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 A glass-capillary microfluidic device is used for enzyme encapsulation in liposomes 
 The enzyme (SOD) retains its enzymatic activity after encapsulation 
 SOD-loaded liposomes (SOD@Lip) present an effective anti-inflammatory property 




The biopharmaceuticals market is constantly growing. Despite their advantages over the 
conventional drugs, biopharmaceuticals have short biological half-lifes, which can be 
increased using liposomes. However, the common bulk methods to produce 
biopharmaceuticals-loaded liposomes result in lost of encapsulation efficiency (E.E.), 
resulting in an expensive process. Herein, the encapsulation of a therapeutic enzyme in 
liposomes is proposed, using a glass-capillary microfluidic technique. Cu,Zn- Superoxide 
dismutase (SOD) is successfully encapsulated into liposomes (SOD@Liposomes). 
SOD@Liposomes with a mean size of 135 ± 41 nm, a polydispersity index of 0.13 ± 0.01, 











show, through an ear edema model, that SOD@Liposomes administered by the intravenous 
route enable an edema inhibition of 65 %  8 %, over the 20 %  13 % of SOD in its free 
form. The histopathological analyses show a higher inflammatory cell accumulation on the 
ear treated with SOD in its free form, than treated with SOD@Liposomes. Overall, this work 
highlights the potential of microfluidics for the production of enzyme-loaded liposomes with 
high encapsulation efficiency, with the intrinsic advantages of the low time-consuming and 
easily upscaling microfluidic assembly method. 
 
 








Biopharmaceutical drugs, such as nucleic acids, monoclonal antibodies and therapeutic 
enzymes, are one of the fastest growing areas on the pharmaceutical industry [1]. Comparing 
with the synthetic drugs, biopharmaceuticals exhibits higher activity, selectivity and lower 
side effects [2]. However, biopharmaceuticals can present low oral bioavailability , instability 
in biological fluids and short biological half-times, leading to a deficient systemic delivery 
and requiring high doses to obtain an efficient therapeutic effect [3,4]. Moreover, depending 
on the route of administration, biopharmaceuticals can suffer degradation and low absorption 
[5,6]. These issues can be easily overcome when a suitable drug delivery system (DDS) is 
developed to a targeted and efficient transport of the biopharmaceuticals [7]. Liposomes, 
introduced for the first time by Bangham and co-worker [8] at the beginning of the 1960s, 
have been widely used on the pharmaceutical field [9–11]. Liposomes are able to carry both 
hydrophobic and hydrophilic active compounds in the lipidic bilayer and into the inner 











the drugs [12–14]. For this reason, the application of liposomes as a versatile drug delivery 
system has increased over the last decades. For example, the encapsulation of 
biopharmaceuticals in liposomes leads to a modification in their pharmacokinetics and 
pharmacodynamics, improving their therapeutic activity [11]. Mokhtarieh et al. have 
reported that the encapsulation of siRNA in liposomes prevented it from the RNase 
degradation and elimination [15]. Another example is related with the Cu,Zn-Superoxide 
dismutase (SOD). SOD is an enzyme with a molecular weight of 32.5 kDa that catalyzes the 
dismutation of anion superoxide radical in molecular oxygen and hydrogen peroxide. This 
enzyme is widely used on the treatment of reactive oxygen species (ROS)-mediated diseases, 
such as rheumatoid arthritis [16,17], inflammation [18,19] and ischemia-reperfusion injury 
[18,19]. However, the administration of SOD without a drug delivery system presents some 
disadvantages, such as the short half-life in the bloodstream (~6 min in rats and 25 min in 
humans) [20,21], low accumulation in affected areas and rapid renal filtration [16]. Previous 
studies have reported the importance of the use of PEGylated liposomes as a carrier for SOD 
on the improvement of the enzyme biodistribution and its therapeutic effect in inflammatory 
processes, increasing its half-life up to 20 h [17,22,23]. In addition, the presence of PEG on 
the surface of the liposomes plays an important role on the administration of SOD-loaded 
liposomes, since it avoids the liposomes opsonization by the mononuclear phagocyte system 
(MPS) [24,25]. For this reason, the application of liposomes in the delivery of 
biopharmaceuticals has aroused a particular interest. The common bulk techniques for the 
production of liposomes rely on the thin-film hydration [23,26], reverse phase evaporation 
[27,28] and ethanol injection [29]. Apart from the fact that post-processing steps, such as 
high pressure extrusion [30], are required to obtain a better control of size and polydispersity 
index (PdI), these techniques also involve the use of organic solvents often resulting in an 
enzyme inactivation during the process [31].  
Moreover, the saturation curve of the enzyme concentration in the inner aqueous 
space and the technical compromise between the efficient encapsulation (E.E.) and the small 
size of the liposomes [23], make reaching a stable and E.E. of macromolecules in liposomes 
challenging [32]. Previous works have demonstrated that bulk methods result in enzyme-
loaded liposomes with low E.E. for small liposomes due to the sizing of the liposomes by 











sizing on the E.E, where it is notorious that the lesser the need of sizing (less extrusion 
processes) of the liposomes, the higher the E.E. of SOD. For example, Corvo et al. obtained 
an E.E of 821 %, 27 ± 3% and 20 % for SOD-loaded liposomes with 110 ± 10 nm [23], 230 
± 90 nm [17] and 200 ± 20 nm [22], respectively. York-Duran et al. obtained an E.E. of 3.0 
± 0.8 % for catalase-loaded liposomes size between 110 and 120 nm [33]. Moreover, 
Morozova et al. reported an E.E. about 25 % for enzyme-loaded liposomes with 218 ± 6 nm 
[34]. 
 Microfluidics is an emerging technology, which enables the manipulation of fluids 
(in nanoliters scale) in micrometer channels [35]. Over the last years, this technique has 
gained a special attention on the biomedical field, since it can be widely used for the 
production of polymeric nano/micro-particles, due to the advantages of being a continuous 
process when compared to the current bulk methods [36]. High batch-to-batch 
reproducibility, higher process control, easy scalability and no requirement of post-
processing steps are some of the advantages that microfluidics can offer [37,38]. 
Polydimethylsiloxane (PDMS), glass and silica, are the common material used on the 
manufacturing of microfluidic devices [39–41]. Upon contact with organic solvents, acids or 
bases, PDMS can swell or be degraded [42] and, due to its hydrophobic nature, the polymers 
tend to aggregate on the walls of the device [43]. To overcome these main drawbacks, 
borosilicate glass capillary can be used. Glass is cheap, inert to chemical solvents and does 
not swell in contact with solvents [36,42]. The application of the microfluidics for the 
liposomes production, specifically glass-capillary microfluidic devices, has been reported 
[44–46]. Through a nanoprecipitation method [47,48] it is possible to produce liposomes in 
a single step process [49,50]. 
 In this work, we propose the production of enzyme-loaded liposomes 
(SOD@Liposomes) with similar physico-chemical properties of the commonly produced 
ones by bulk methods, but with higher efficiency encapsulation and process yield, using a 
glass-capillary microfluidic device (Scheme 1). We aimed to obtain a continuous and simple 
one-step method that offers a scalable, reproducible, time and cost efficient and a high 











Scheme 1: Schematic representation of the microfluidic process on the encapsulation of SOD in 
PEGylated liposomes (not to scale). Lipids and cholesterol were dissolved in ethanol (inner phase), 
whereas SOD was dissolved in a saline citric buffer at pH 6 (outer phase).Through the 
nanoprecipitation technique, the lipids self-assembled, enclosing the enzyme in the aqueous inner 
phase (SOD@Liposomes). SOD@Liposomes were then collected by the collecting capillary.  
 
2. Materials and methods 
2.1. Materials 
Egg-phosphatidylcholine (E-PC) and distearoylphosphatidylethanolamine-
poly(ethyleneglycol)2000 (DSPE-PEG2000) were obtained from Lipoid (Germany). Cholesterol 
(Chol), bovine erythrocytes Cu, Zn-superoxide dismutase, 300 kU (SOD), 2-(4-(2-
hydroxyethyl) piperazin-1-yl) ethanesulfonic acid (HEPES), citric acid, anthralin and sodium 
chloride were purchased from Sigma-Aldrich (USA). Hank’s balanced salt solution (HBSS) 
and phosphate buffer saline (PBS) were purchased from Life Technologies (USA). Triton® 
X-100 was purchased from Merck Millipore (Germany). Dulbecco’s Modified Eagle’s 
medium (DMEM), L-glutamine, non-essential amino acids, penicillin (100 IU mL-1) and 
streptomycin (100 mg mL-1), ethylenediamine tetraacetic acid (EDTA) and trypsin–EDTA 
were purchased from HyClone (USA). Human colon carcinoma (Caco-2) and the human 
colorectal adenocarcinoma modified with methotrexate (HT29-MTX) cells were purchased 















The liposomes and SOD-loaded liposomes were prepared by the nanoprecipitation method, 
[47] using a modified co-flow microfluidic glass-capillary device. Briefly, a borosilicate 
glass capillary (inner capillary with a diameter of 100 µm) was placed in front of another 
glass capillary with an inner diameter of 120 µm (collecting capillary), slightly deviated. 
Both were inserted into a glass capillary (outer capillary) with an inner diameter of 1000 µm. 
Then, a mixture of E-PC, DSPE-PEG2000 and Chol (molar ratio 1.85:0.15:1, respectively) 
was dissolved in ethanol, in a total lipid concentration of 48.0 µmol mL-1 and injected in the 
inner phase. Alike, a saline citric acid buffer (145 mM of NaCl, 10 mM of Citric Acid, pH 
6.0) without and with SOD, in a final concentration of 75 µg mL-1, was injected in the outer 
phase. Both streams were injected with flow rates of 25 mL h-1 and a flow rate ratio (FRR) 
of 1. The SOD@Liposomes from the collecting capillary and non-encapsulated enzyme was 
separated from the liposomes by ultracentrifugation twice (Optima L-80, XP Ultracentrifuge, 
Beckman Coulter, CA, USA), at 135 000g at 4 °C for 2 h. Then, the SOD@Liposomes pellet 
was re-suspended in a saline citric acid buffer solution at pH 6.0. The experiment was 
performed in triplicate.  
2.2.2. Characterization of liposomes and SOD@Liposomes  
The liposomal formulations were characterized in terms of their morphology and 
phospholipid concentration. SOD@Liposomes were also characterized in terms of protein 
concentration and enzyme activity. Liposome size, determined as Z-average, the PdI, as a 
measure of the particle size distribution that can range from 0 (monodisperse) and 1.0 
(polydisperse), and the surface charge (zeta (ζ)-potential), were determined using Zetasizer 
Nano ZS (Malvern Instruments Ltd., UK). The structure of the SOD@Liposomes was 
confirmed using cryo-transmission electron microscope (Cryo-TEM, JEOL JEM-3200FSC, 
JEOL, Tokyo, Japan). Briefly, prior to use, vitrified specimens were prepared using an 
automated FEI Vitrobot device, and Quantifoil 3.5/1 holey carbon copper grids with a hole 
size of 3.5 µm. Then, an aliquot of liposomal suspension was applied on the grid and it was 
blotted twice for 5 sec and then vitrified in a 1:1 mixture of liquid ethane and propane at 180 
°C. The grids with the vitrified liposomes were kept in liquid nitrogen temperature and then 
cryo-transfered to the microscope. Imaging was carried out using a field emission cryo-TEM 










using zero loss energy filtering (omega type) with a slit width of 20 eV. Micrographs were 
recorded using a Gatan Ultrascan 4000 CCD camera (Gatan Inc., Pleasanton, CA, USA). The 
specimen temperature was maintained at 187 °C during the imaging. The images were 
treated using Gatan Microscopy Suite Software (Gatan Inc). 
 The concentration of phospholipids was determined by the Rouser’s method [51]. 
The enzyme was quantified with a modified Lowry’s method [52], where liposomes were 
previously disrupted with 2 % (v/v) Triton® X-100 and 20 % (v/v) of sodium dodecylsulphate 
(SDS) [53]. The E.E was calculated as follows (Eq. 1): 






















is the SOD-to-lipid ratio after 
the removal of the non-encapsulated enzyme.   
 The SOD enzymatic activity from SOD@Liposomes was evaluated using the SOD 
assay kit (19160-1KT-F, Sigma-Aldrich), where liposomes were previously disrupted with 2 
% (v/v) Triton® X-100 and 20 % (v/v) of SDS.  
2.2.3. Cell lines and cell culture conditions  
HT29-MTX (passage #32) and Caco-2 (passages #35-40) were separately cultured in a 75 
cm2 culture flask in DMEM containing 10% of fetal bovine serum (FBS), 1 % (v/v) of L-
glutamine, 1% (v/v) of penicillin and streptomycin and 1 % (v/v) of non-essential amino 
acids. The cells were left to grow under 37°C, in 5 % of CO2 and relative humidity of 95 %. 
The cell culture medium was changed every other day. Sub-culturing was performed using 
trypsin-PBS-EDTA when confluency reached 80 %.  
2.2.4. In vitro cytotoxic studies 
The cell viability studies were carried out using CellTiter-Glo® assay reagent (previously 
diluted with HBSS−HEPES buffer at pH 7.4,  in a ratio of 1:1 (v/v)). Briefly, 5 × 104 cells of 
Caco-2 and HT29-MTX cell lines were individually seeded in 96-well plates (Corning Inc., 
USA), and left to attach for 24 h. Afterwards, the medium was discarded, and the cells were 













concentration ranging from 2.5 to 15 µg mL-1 were added to the cells. The cells were 
incubated at 6 h or 24 h, under 37 °C. After the incubation time, cells were washed twice 
with fresh HBSS−HEPES buffer, and 100 µL of CellTiter-Glo® was added. The plates were 
lightly shaken for 2 min. HBSS−HEPES and 1% (v/v) Triton® X-100 solutions were used as 
positive and negative controls, respectively. The luminescence values were measured using 
a Varioskan Flash Multimode Reader (Thermo Fisher Scientific, USA). All the experiments 
were performed at least in triplicate. 
2.2.5. Animal experiments 
NMRI female mice (6 weeks of age) were purchased from Charles River (France). The 
animals were used after one week for acclimatization on the laboratory environment (21 ± 1 
°C and 50 ± 4 % of relative humidity; 12 h day/night cycle and water and food ad libitum). 
All animal experiments were conducted according to the animal welfare organ of the Faculty 
of Pharmacy, Universidade de Lisboa, approved by the competent national authority Direção 
Geral de Alimentação e Veterinária (DGAV) and in accordance with the EU Directive 
(2010/63/UE) and Portuguese laws (DL 113/2013, 2880/2015, 260/2016, and 1/2019). 
2.2.6. Anthralin induced ear edema model  
The anthralin induced ear edema model was performed according to Lange et al.[54], 
modified by Ascenso et al. [55]. When applied onto the ear skin, anthralin provokes an ear 
swelling, induced by ROS in the skin. The animals were anesthetized, and the thickness of 
both ears was measured using a Mitutoyo® dial gage. Six groups of animals (n = 5) were 
tested: (i) 7.3 µg of SOD (180 µL) of SOD@Liposomes were administered intravenously 
(i.v.); (ii) 7.3 µg of SOD (180 µL) of SOD previously dissolved in citrate buffer (free SOD 
(i.v.)) were administered i.v.; (iii) 7.3 µg of SOD (180 µL) of SOD@Liposomes were 
administered intraperitoneally (i.p.); (iv) 7.3 µg of SOD (180 µL) of SOD previously 
dissolved in citrate buffer (free SOD (i.p.)), administrated by i.p.; (v) 10 µL of 0.1% 
betamethasone solution was applied on the right ear (positive control); and (vi) one group of 
animals received no treatment. Treatments were administered 1 h before the challenge for 
groups from (i) to (iv). Group (v) received the application 1 h after the challenge. The 











(4:1), was topically applied on the pinna of both ears in all groups. Mice were kept in 
individual cages and, 24 h after the challenge, the resulting edema was determined through 
the measurement of the ears thickness (in triplicate). The percentage of the edema inhibition 
was determined by the comparison between the thickness of non-treated ears (negative 
control) and ear thickness of the treated animals.  
2.2.7. Histopathological analysis  
After the experiments, mice were euthanized with prior anesthesia with isoflurane and the 
ear pinna were collected. Then, the ears were fixed in formalin and submitted to 
histopathological analysis. Hematoxylin and eosin stain were used.   
2.2.8. Statistical analysis 
All results are expressed as mean ± standard deviation (S.D.), except the animal experiments 
which are expressed as mean ± standard error of the mean (SEM). To analyze the data, 
analysis of variance (ANOVA) followed by Bonferroni post test (GraphPadPrism, GraphPad 
software Inc., CA, USA) was used. The level of significance was set at the probabilities of 
*p< 0.05, **p< 0.01 and ***p< 0.001.  
 
 
3. Results and Discussion 
3.1. Characterization of Liposomes and SOD@Liposomes 
The encapsulation of SOD in liposomes was achieved through a nanoprecipitation method 
[47]. In fact, into the glass-capillary microfluidic device, upon contact with the saline citrate 
buffer, the polarity of the lipid-based ethanolic solution increased. Lipids self-assembled, 
enclosing the buffered SOD (SOD@Liposomes).  Previous works have demonstrated that, 
due to the physicochemical properties of the SOD and liposomes, SOD is exclusively 
encapsulated in the inner aqueous compartment [17,23,56]. In the case of empty liposomes 
(control), a buffered aqueous core was enclosed in spherical vesicles [37,57]. The obtained 
SOD@Liposomes were characterized and the results are shown in Table 1. 
SOD@Liposomes presented an average size of 135 ± 41 nm, and a PdI of 0.128 ± 0.010, 











± 0.016. Even though it would be expected that SOD@Liposomes presented higher diameter 
values, the difference between the size of SOD@Liposomes and empty liposomes is within 
the variability with the variability among the batches. Both formulations presented a near 
zero ζ- potential value, as expected for PEG coated liposomes. The E.E. for 
SOD@Liposomes was 59 ± 6 % (Table 1). Previous works, using bulk methods for 
encapsulation of SOD in liposomes, have reported different and lower E.E.. Corvo et al. 
reported an E.E. of 21 ± 2 % for SOD@Liposomes (lipid concentration of 48 µmol mL-1) 
with a mean size of 110 ± 10 nm [23], whereas Rengel et al. reported for a similar nanosytem 
an E.E. of about 13% for a mean size of 90 ± 60 nm [58]. Simões et al. also reported 
SOD@Liposomes with a mean size of 149 ± 9 nm and an E.E. of 34 ± 2 % [59] and, more 
recently, Marcelino et al. obtained enzyme-loaded liposomes with an E.E. of 9 ± 2 % for a 
mean size of 140 ± 20 nm [60]. Previous works have also demonstrated that neutral 
SOD@Liposomes formulations are stable over the time, at 4 ºC [20,61–63]. 
 An important consideration in this system is the retention of SOD enzymatic activity 
after the microfluidic process. Although the mixing time is fast, in this method ethanol is 
used as solvent in the inner phase, which might represent a threat for the enzyme activity. In 
this way, the SOD activity was evaluated and an enzymatic activity of 82 ± 3 % was observed 
(previous works reported a activity between 90– 95 % for bulk methods [20,23,58]), attesting 
that the microfluidic technique does not compromise the activity of the enzyme [64]. As such, 
the production of SOD@Liposomes through the glass-capillary microfluidic process 
represents a notable improvement on the encapsulation of the enzyme over the formulations 
(with similar physico-chemical properties) produced by bulk process.  
   















SOD@Liposomes 135 ± 41 0.13 ± 0.01 - 0.6 ± 0.2 0.92 ± 0.10 59 ± 6 82 ± 3 
Liposomes 171 ± 14 0.14 ± 0.02 0.4 ± 0.8 - - - 
The results are expressed as mean ± S.D (n = 3) 











(Prot/Lip)f: Final enzyme to lipid ratio considering the final lipid concentration value.  
Ret. Act.: Retained enzymatic activity.*n= two independent batches. 
 
 
In order to confirm the structure of the SOD@Liposomes, a Cryo-TEM analysis was 
performed (Figure 1). The image shows a thin single-wall structure enclosing a vesicle with 
a mean size of 158 ± 7 nm, determined by Gatan Microscopy Suite software.  
 
Figure 1: Cryo-TEM analysis of SOD@Liposomes (48.0 µmol mL-1) vitrified in a 1:1 
mixture of liquid ethane and propane at 180 °C. 
 
3.2. In vitro cytotoxic studies 
Cytotoxicity tests were performed using the CellTiter-Glo luminescence assay. Briefly, the 
Caco-2 and HT29-MTX cell lines (used in this work as a cellular model) were exposed to 
various concentrations of enzyme-loaded liposomes and empty liposomes, ranging from an 
equivalent concentration of the enzyme from 2.5 µg mL-1 to 15 µg mL-1, for 6 h and 24 h. 
After 6 h, both cell lines presented higher viability for SOD@Liposomes than for empty 
liposomes, 13 ± 9 % and  14 ± 4 %, for Caco-2 and HT29-MTX cell lines, respectively 
(Figure 2). This was an expected result due to the antioxidant capacity of SOD. Since cancer 
cells can produce higher levels of ROS, leading to an oxidative stress, a consequent cell 











resulting also in a reduction of the oxidative stress. Therefore, it is expected an increase in 
the cell viability [66]. After 24 h, HT29-MTX cells presented a slight decrease of the cell 
viability at higher concentration. This can be related with the toxicity of the liposomes at 
high concentrations, as also obverved before by Adamczak et al. [67]. For a lower 
concentration of neutral liposomes, a decrease of ~25 % was observed. Since the viability 
remained above 79 %, the liposomes are considered non-toxic, according to the guidelines 
from the regulatory authorities [68]. Moreover, SOD@liposomes have already been used for 
longer treatment periods and no toxicity was observed  [69]. Therefore, next the in vivo 
studies were pursued.  
 
 
Figure 2: HT29-MTX and Caco-2 cells lines viability when exposed to different 











at 37 °C. All the data were compared to the negative control (HBSS-HEPES at pH 7.4). The 
level of significance was set at the probabilities of *p< 0.05, **p< 0.01 and ***p< 0.001. 
The results are expressed as mean ± S.D. (n = 3). 
3.3. In vivo activity 
 The animal experiments using the anthralin ear edema model were conducted for 24 
h to evaluate the anti-inflammatory effect of SOD formulated in liposomes, based on its 
antioxidant properties. Among the animal models available for the evaluation of anti-
inflammatory agents, the anthralin (1,8- dihydroxy-9-anthrone)-induced ear swelling is an 
important tool to evaluate the relationship between anthralin-induced oxidative stress and ear 
swelling. The ear swelling assay was performed according to the method described by Lange 
et al. [54] also tested for topical antioxidants application [55,70]. In fact, oxidative stress 
plays an important role in chemically induced inflammation as occurring with anthralin 
contact with the skin, responsible for the generation of ROS within the skin. Betamethasone 
was reported to reduce mice ear edema in this cutaneous inflammation model [55,70,71] and 
was used in this assay as a positive control to validate the model. The experimental 
inflammation evoked by the application of anthralin (epidermal hyperplasia and 
inflammatory cell infiltration) is remarkably reduced by betamethasone topical application. 
The work of Lange and co-workers presented systemic antioxidant administration to provide 
an opportunity to treat the oxidative stress generated at the site of anthralin application that 
can change the expression of dermal chemokines responsible for the recruitment of 
inflammatory cells [54]. In this work we have confirmed the usefulness of systemic SOD to 
treat local inflammation. The well-known biological activity of SOD has a bell-shape curve. 
It is known that doses ranging from 30 and 400 g kg-1 are in the high activity profile [21]. 
Thus, we administered 180 L (7.3 g) of SOD@Liposomes and SOD dissolved in the citrate 
buffer (free SOD), equivalent to a dose of 300 g kg-1 in each mouse. The i.v. and i.p. 
administrations were performed 1 h before the application of the challenge, since the 
inflammation onset occurs 24 h after the challenge. Figure 3 shows the edema inhibition 
percentage for each group. As expectable, it is possible to observe that SOD@Liposomes 
presented a higher edema inhibition (65 %  8 %), compared to SOD in its free form (20 % 










the fast SOD clearance [17,20] and the presence of PEG that can also increase the liposomes 
circulation in the bloodstream over 24 h, improving the therapeutic effect of 
SOD@Liposomes [23]. Moreover, the improvement of the therapeutic effect of the 
SOD@Liposomes is also related with the enhanced permeability and retention effect. This 
effect allows the extravasation and the accumulation of the PEGylated liposomes in the 
inflamed tissues, enabling a more efficient enzyme delivery [72,73].  
 The administration of SOD@Liposomes by different routes of administration was 
also assessed. Figure 3 shows a significant higher edema inhibition (*p<0.05) for 
SOD@Liposomes administered i.v. over the i.p. route. SOD@Liposomes (i.v.) showed an 
edema inhibition of 65 %  8 %, whereas SOD@Liposomes (i.p.) showed an edema 
inhibition of 33 %  13 %. Such difference is related with the different biodistribution of 
SOD@Liposomes, regarding the administration route. Previous studies have demonstrated 
that nanoparticles administrated by i.p. tend to accumulate in the local tissues in the 
abdominal cavity [74]. In addition, the peritoneal-blood barrier can limit the transport of the 
liposomes from the peritoneal cavity into the bloodstream [75]. Allen et al. also observed an 
increase of the half-life of the liposomes administered by i.p. of 9 h, contrasting with the half-
life of 20.4 h from the liposomes administered by i.v. [76] As such, by i.v. administration, 
the distribution of the liposomes throughout the bloodstream is more effective than by i.p., 
supporting the observed values. Both in vitro and in vivo studies highlight the superiority of 





















Figure 3: Effect of the treatment with i.v. administration of SOD@Liposomes (SOD-Liposomes 
(i.v.)), i.v. administration of SOD solution (Free SOD (i.v.)), i.p. administration of SOD@Liposomes 
(SOD- Liposomes (i.p.)), i.p. administration of SOD solution (Free SOD (i.p.)), topical application 
of betamethasone (positive control), 24 h after mice ear challenge with 10 mM of anthralin, expressed 
as percentage of ear edema inhibition. Each result represents the mean and SEM (n = 5), *p<0.05 and 
***p<0.001. 
Histological analyses of the ears, collected after 24 h of challenge application, confirmed the 
superior efficacy of the encapsulated SOD in inhibiting the edema formation, in comparison 
to the SOD administered in the free form (Figure 4). The negative control (anthralin applied 
on the ear, without treatment) showed mild acanthosis (increase of the cell layer), 
papillomatosis (external overgrowth of epidermis with elongation of dermal papillae) and 
epidermal hyperkeratosis (increase of the thickness of the cornified layer) (Figure 4A). The 
free SOD (i.v.) treated animals (Figure 4B) also presented a mixed focal inflammation 
(acanthosis, papillomatosis and hyperkeratosis), although the papillomatosis was not so 
evident. In addition, an epidermal reaction was also observed. Ears from animals treated with 
SOD@Liposomes (i.v.) (Figure 4C) showed a focal ulceration of epidermis with underlying 
mixed inflammation. These observations are in accordance with the previous results from the 










were treated with SOD solution, without liposomes. The images from SOD@Liposomes 
(i.p.) treated animals (Figure 4D) showed only a slight focal epidermal hyperkeratosis and 
no other significant changes. Regarding the free SOD (i.p.) treated mice (Figure 4E), a mild 
epidermal hyperkeratosis was observed, corrobarationg the need of liposomes as a drug 
delivery system that enhances the therapeutic effect of the enzyme. Finally, as expected, the 
positive control (betamethasone) did not exhibit cellular infiltration or edema (Figure 4F). 
The measurement of the ear edema pointed to the superiority of the i.v administration of 
SOD@Liposomes over the i.p. administration. However, the cellular events assessed by 
histological analysis do not corroborate these findings. In any case, the superiority of 




Figure 4: Representative microphotographs of longitudinal sections (100) of the mouse ear 
pinna from (A) negative control; (B) free SOD (i.v.); (C) SOD@liposomes (i.v.); (D) 
SOD@Liposomes (i.p.); (E) free SOD (i.p.); and (F) positive control (betamethasone), after 
24 h of challenge application. The edema is highlighted by the orange arrows, whereas the 















In this work, the microfluidic technique was used to encapsulate SOD in PEGylated 
liposomes (SOD@Liposomes). In this manner, SOD was efficiently encapsulated (59±6 %), 
showing higher E.E. than SOD@Liposomes with similar physicochemical properties from 
conventional processes. Although the process requires the use of an organic solvent, the 
SOD@Liposomes retains the enzymatic activity (82 ± 3 %). This work highlights the 
potential of the microfluidic technique to overcome the high loss of enzyme associated to the 
common batch production of liposomal formulations, which makes the process cheaper. The 
produced nanosystems also showed high cytocompatibility in the cells tested. In vivo 
experiments to test the anti-inflammatory properties of SOD@Liposomes showed the 
inhibition of 65  8 % for animals treated with SOD@Liposomes administered i.v. The 
histopathological studies also showed the effectiveness of the administration of the 
SOD@Liposomes, compared to the SOD administered on its free form, as a result of the 
decreased infiltration of inflammatory cells. Overall, microfluidics showed to be a suitable 
and efficient technique to encapsulate SOD into liposomes, which represent a promising 
approach to encapsulate therapeutic enzymes in liposomes anti-inflammatory applications in 
vivo. 
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